Supramolecular assembly, preparation method thereof, and cosmetic composition containing the same
Patent Information
- Application Number
- HK42026125248
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-06-24
- Publication Date
- 2026-09-11
AI Technical Summary
Azelaic acid has very low solubility in water and a high melting point, making it difficult to prepare water-based cosmetics. Furthermore, existing methods have stability issues and risks of skin irritation.
The water solubility of azelaic acid is improved and its stability is maintained by forming supramolecular aggregates with heterocyclic amino acids such as proline as shown in general formula (I), followed by liquid-assisted grinding or cooling crystallization.
Azelaic acid has at least 15% improved water solubility, and its supramolecular aggregates do not cause inflammation when used on the skin, providing good stability and safety.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present disclosure relates generally to the field of supramolecular chemistry, and in particular to a novel supramolecular aggregate, a method for preparing the same and a cosmetic composition containing the same. BACKGROUND
[0002] Azelaic acid, also known as Azelaic acid, has a molecular formula of C9H 16 O4, due to its excellent antibacterial properties, it is widely used in the field of cosmetics. However, azelaic acid has very low solubility in water, only about 2-3 grams per liter of water, which makes it difficult to prepare water-based cosmetics. And because its melting point is as high as 131-134℃, it needs higher temperature to melt during heating, which increases the complexity and energy consumption of the preparation process.
[0003] In order to improve the water solubility of azelaic acid, various attempts have been made. CN113248364A discloses a method for solubilizing azelaic acid, which includes compounding with alkaline substances. CN112624918A discloses a method for forming a supramolecular co-crystal of azelaic acid with pyridine carboxamide and other organic compounds containing amino groups. CN117567763A discloses a supramolecular system formed by azelaic acid, lactic acid and panthenol. However, the methods in CN113248364A and CN112624918A are prone to decomposition of azelaic acid due to the presence of alkaline environment, not only reducing the efficacy, but also raising concerns about stability. Furthermore, the use of lactic acid in the method described in CN117567763A can damage the skin barrier if used for a long time, causing the skin to become weak and vulnerable to external harmful substances. This in turn can also cause skin inflammation or other skin problems. Therefore, the prior art still needs to be improved and developed. SUMMARY
[0004] The purpose of the present application is to solve the problems existing in the prior art, to provide a novel azelaic acid supramolecular aggregate which can improve the solubility of azelaic acid in water and has good stability, and does not cause the above-mentioned skin problems even if used for a long time.
[0005] The present inventors have conducted in-depth research on the method for forming azelaic acid supramolecular aggregates, and as a result, it has been unexpectedly found that azelaic acid and heterocyclic amino acids represented by the following general formula (I) can form a novel supramolecular aggregate which can improve the solubility of azelaic acid in water and has good stability, and does not cause skin inflammation or other skin problems even if used for a long time.
[0006] In a first aspect, the present disclosure provides a supramolecular aggregate formed by azelaic acid and at least one heterocyclic amino acid represented by the general formula (I),
[0007]
[0008] wherein R1and R2each independently represent hydrogen or hydroxyl, and at least one of R1and R2represents hydrogen; and
[0009] wherein the powder X-ray diffraction pattern of the aggregate comprises characteristic peaks at 2-theta of 5.7°±0.2° and 21.8°±0.2°.
[0010] According to some embodiments, the powder X-ray diffraction pattern of the aggregate further comprises at least 2, preferably at least 4 characteristic peaks at 2-theta of 8.5°±0.2°, 9.4°±0.2°, 16.7°±0.2°, 17.6°±0.2°, 18.5°±0.2°, 19.4°±0.2°, 20.3°±0.2°, 21.1°±0.2°, 23.0°±0.2°, 23.6°±0.2°, 27.3°±0.2° and 28.3°±0.2°.
[0011] According to some embodiments, the powder X-ray diffraction pattern of the aggregate further comprises at least 2, preferably at least 4 characteristic peaks at 2-theta of 16.6°±0.2°, 17.5°±0.2°, 19.3°±0.2° and 22.9°±0.2°.
[0012] According to some embodiments, the powder X-ray diffraction pattern of the aggregate further comprises at least 2, preferably at least 4 characteristic peaks at 2-theta of 8.3°±0.2°, 9.3°±0.2°, 16.5°±0.2°, 17.4°±0.2°, 18.0°±0.2°, 18.4°±0.2°, 19.0°±0.2°, 22.8°±0.2°, 23.4°±0.2°, 27.1°±0.2° and 28.1°±0.2°.
[0013] According to some embodiments, the powder X-ray diffraction pattern of the aggregate comprises characteristic peaks at 2-theta of 5.7°±0.2°, 8.5°±0.2°, 9.4°±0.2°, 16.7°±0.2°, 17.6°±0.2°, 18.5°±0.2°, 19.4°±0.2°, 20.3°±0.2°, 21.1°±0.2°, 21.8°±0.2°, 23.0°±0.2°, 23.6°±0.2°, 27.3°±0.2° and 28.3°±0.2°.
[0014] According to some embodiments, the powder X-ray diffraction pattern of the aggregate comprises characteristic peaks at 2-theta of 5.5°±0.2°, 16.6°±0.2°, 17.5°±0.2°, 19.3°±0.2°, 21.7°±0.2° and 22.9°±0.2°.
[0015] According to some embodiments, the powder X-ray diffraction pattern of the aggregate comprises characteristic peaks at 2-theta of 5.5°±0.2°, 8.3°±0.2°, 9.3°±0.2°, 16.5°±0.2°, 17.4°±0.2°, 18.0°±0.2°, 18.4°±0.2°, 19.0°±0.2°, 21.7°±0.2°, 22.8°±0.2°, 23.4°±0.2°, 27.1°±0.2° and 28.1°±0.2°.
[0016] According to some embodiments, the heterocyclic amino acid is proline or hydroxyproline, preferably proline.
[0017] According to some embodiments, the molar ratio of azelaic acid to proline is 1:5 to 5:1, preferably 1:2 to 2:1, more preferably 1:1 to 2:1.
[0018] According to some embodiments, the aggregate shows one endothermic peak in its DSC pattern at a temperature of 76°C to 86°C.
[0019] According to some embodiments, the aggregate further shows one endothermic peak in its DSC pattern at a temperature of 94°C to 103°C.
[0020] According to some embodiments, the aggregate has only one endothermic peak in its DSC pattern at a temperature of 78°C ± 2°C.
[0021] In a second aspect, the present disclosure further provides a method for preparing a supramolecular aggregate from azelaic acid and a heterocyclic amino acid, comprising the following steps:
[0022] 1) mixing azelaic acid with at least one heterocyclic amino acid represented by the following general formula (I) at a molar ratio of 1:5 to 5:1, preferably 1:2 to 2:1, more preferably 1:1 to 2:1, more preferably 1:1 to obtain a mixture;
[0023]
[0024] wherein R1and R2each independently represent hydrogen or hydroxyl, and at least one of R1and R2represents hydrogen; and
[0025] 2) subjecting the mixture to liquid-assisted milling or cooling crystallization to obtain a supramolecular aggregate.
[0026] According to some embodiments, the liquid-assisted grinding is performed using a lower saturated alkyl alcohol as grinding liquid, wherein the ratio of the volume of the lower saturated alkyl alcohol to the mass of the mixture is 0.1 to 0.5 ml / g.
[0027] According to some embodiments, the lower saturated alkyl alcohol is ethanol.
[0028] According to some embodiments, the heterocyclic amino acid is proline or hydroxyproline, preferably proline.
[0029] In a third aspect, the present disclosure further provides a cosmetic composition comprising the supramolecular aggregate of the present disclosure.
[0030] According to some embodiments, the composition further comprises at least one active ingredient selected from the group consisting of surfactants, humectants, non-volatile oils, antioxidants, UV screening agents, anti-inflammatory agents, natural extracts, ferments, vitamins, skin conditioning agents, preservatives, thickening agents, and mixtures thereof.
[0031] Other subjects and characteristics, aspects and advantages of the present application will emerge even more clearly on reading the description and the examples that follow. BRIEF DESCRIPTION OF DRAWINGS
[0032] The accompanying drawings are included to provide a further understanding of embodiments of the present disclosure and constitute a part of the specification. They illustrate embodiments of the present disclosure and together with the description, explain the principles of the present disclosure. In the drawings:
[0033] Figure 1 DSC patterns of azelaic acid and L-proline as raw materials, and supramolecular aggregates prepared by different raw material ratios and preparation methods are shown.
[0034] Figure 2 Powder X-ray diffraction patterns of azelaic acid and L-proline as raw materials, and supramolecular aggregates prepared by different raw material ratios and preparation methods are shown. Figure 3 Powder X-ray diffraction patterns of azelaic acid and L-lysine as raw materials, and supramolecular aggregates prepared in Comparative Example 1 are shown. DETAILED DESCRIPTION
[0035] I. DEFINITIONS
[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. If the definitions of the terms in the specification conflict with the meanings commonly used by those skilled in the art, the definitions in the specification are intended to control.
[0037] Throughout this application, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of all the stated features, or optional, additional, unspecified features. The use of the term "comprising" as used in the specification also discloses embodiments in which the stated features are present, but additional, unspecified features are not present (i.e., "consisting of").
[0038] Unless otherwise stated, all numerical values of parameters (e.g., of quantities or conditions) in the specification and claims are to be understood as being modified in all instances by the term "about" and have a meaning, within the context of the disclosure, consistent with the use of such a term in the art. Thus, for example, "about 100-220" means 90-242, and "about 10" means 9-11, unless otherwise indicated. Accordingly, the numerical values described in this detailed description are approximations and can vary depending upon the requirements of the particular application. At the very least, each numerical value should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Further, the ranges and amounts of the disclosure and claims are intended to encompass all ranges and amounts that fall within the scope of the disclosure and are intended to be construed as if the disclosure specifically stated such ranges and amounts. For example, a range of 0-10 is intended to encompass all integer and fractional values between 0 and 10, e.g., 1, 2, 3, 4, and any sub-range of any two of these values, e.g., 1-2, 2-4, etc., all integer and fractional values between 0 and 10, e.g., 1.5, 2.3, 4.57, 6.1113, etc., and the end points 0 and 10.
[0039] The term "supramolecular aggregate" as used herein means an aggregate of two or more molecules that are bound together by intermolecular interactions, such as hydrogen bonding, π-π stacking, van der Waals forces, and other non-covalent bonds.
[0040] The term "co-crystal" as used herein is a morphological description of a supramolecular aggregate and refers to a crystal formed by two or more different molecules bound together in a fixed stoichiometric ratio by non-covalent bonds within the same crystal lattice.
[0041] The term "liquid-assisted grinding" as used herein, also sometimes referred to as "wet grinding," is a technique that involves adding a small amount of solvent and grinding the raw materials to form crystals.
[0042] The term "cooling crystallization" as used herein, also sometimes referred to as "temperature lowering crystallization," is a technique that involves heating a raw material solution to complete dissolution and then lowering the temperature to supersaturate the solution to precipitate crystals.
[0043] II. Supramolecular Aggregates
[0044] Supramolecular aggregates refer to complex, organized aggregates formed by two or more molecules through intermolecular interactions that maintain a certain integrity and have a well-defined microscopic structure and macroscopic properties. These intermolecular interactions can include electrostatic interactions, hydrogen bonding, coordination bonding, van der Waals forces, π-π conjugation, hydrophobic interactions, and other weak intermolecular forces of non-covalent bonds.
[0045] Due to the important role played in the development of raw materials and product upgrading, the application of supramolecular technology in the field of cosmetics has been increasingly widespread. However, according to the technology so far, not all molecules can form supramolecular aggregates, and the selection of suitable object molecules for forming azelaic acid supramolecular aggregates still has difficulties.
[0046] According to a first aspect, the present disclosure provides a supramolecular aggregate formed by azelaic acid and at least one heterocyclic amino acid represented by general formula (I),
[0047]
[0048] wherein R1and R2each independently represent hydrogen or hydroxyl, and at least one of R1and R2represents hydrogen; and
[0049] wherein the powder X-ray diffraction pattern of the aggregate comprises characteristic peaks at 5.7°±0.2° and 21.8°±0.2°.
[0050] Azelaic acid is a dicarboxylic acid obtained by replacing one hydrogen atom on any two carbon atoms of heptane with a carboxyl group. Since heptane has seven carbon atoms, and the substitution position can vary, a variety of possible azelaic acid isomers will be produced. These isomers will be distinguished based on the different positions of the carboxyl group on the heptane carbon chain. Azelaic acid as used herein is intended to encompass all such isomers.
[0051] In a preferred embodiment, the azelaic acid particularly refers to 1,9-azelaic acid. As 1,9-azelaic acid, a commercially available product can be used. For example, azelaic acid supplied by Leyan under the trade name Azelaic acid (hereinafter, sometimes referred to as AZA) is particularly used in the present disclosure.
[0052] In the present disclosure, the heterocyclic amino acid used to form a supramolecular aggregate with azelaic acid has an α-imino acid structure represented by general formula (I).
[0053] In some embodiments, the heterocyclic amino acid is a heterocyclic amino acid represented by general formula (I) in which both R1and R2are hydrogen atoms, i.e., proline. The proline can be any one of L-proline, D-proline, and DL-proline.
[0054] In some embodiments, the heterocyclic amino acid is a heterocyclic amino acid represented by general formula (I) in which either one of R1and R2is a hydroxyl group, i.e., hydroxyproline. Depending on the chiral structure, hydroxyproline includes cis-3-hydroxy-L-proline, cis-4-hydroxy-L-proline, trans-3-hydroxy-L-proline, and trans-4-hydroxy-L-proline.
[0055] In some embodiments, the heterocyclic amino acid used in the present disclosure can be any one of L-proline, D-proline, cis-3-hydroxy-L-proline, cis-4-hydroxy-L-proline, trans-3-hydroxy-L-proline, and trans-4-hydroxy-L-proline.
[0056] In some embodiments, the heterocyclic amino acid used in the present disclosure can be a combination of two or more of L-proline, D-proline, cis-3-hydroxy-L-proline, cis-4-hydroxy-L-proline, trans-3-hydroxy-L-proline, and trans-4-hydroxy-L-proline.
[0057] L-proline is one of the twenty amino acids used for protein synthesis in the human body. It not only has functions such as moisturizing, improving skin texture, and inhibiting skin pigmentation, but also has an extremely low risk factor of 1, so even if it is used for a long time, it is not easy to cause skin problems such as damage to the skin barrier, resulting in weak skin, and triggering skin inflammation. Therefore, in a preferred embodiment, the heterocyclic amino acid used in the present disclosure is preferably L-proline.
[0058] In some embodiments, the molar ratio of azelaic acid to proline in the supramolecular aggregate is 1:5 to 5:1, preferably 1:2 to 2:1, and more preferably 1:1 to 2:1.
[0059] Without wishing to be bound by theory, it is believed that by having an α-imino acid structure, the heterocyclic amino acid in the present disclosure can have intermolecular interaction with the two carboxyl groups in azelaic acid to form a co-crystal, thereby increasing the solubility of azelaic acid and reducing its irritation to the skin. Moreover, due to the α-imino acid structure, the proline used in the present disclosure to form a supramolecular aggregate with azelaic acid is neutral and does not constitute an alkaline environment. Therefore, the absence of an alkaline environment eliminates concerns about the stability of azelaic acid, which is prone to decomposition, resulting in reduced efficacy.
[0060] In some embodiments, by forming a supramolecular aggregate, the solubility of azelaic acid is increased by at least 15%, preferably 17%, and more preferably 19%.
[0061] The expression "the solubility of azelaic acid is increased by at least XX%" used herein means that in the solubility determination described later using the shake flask method and ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS), the solubility of azelaic acid in water in the supramolecular aggregate formed by azelaic acid and the heterocyclic amino acid is increased by at least XX% relative to the solubility of azelaic acid monomer in water.
[0062] The term "XX%" used herein refers to a specific percentage value of the increase in solubility of azelaic acid.
[0063] In some embodiments, the solubility of azelaic acid in water is increased by at least 16%, 17%, or 18% in the supermolecular aggregates formed by azelaic acid and at least one heterocyclic amino acid of Formula (I) relative to the solubility of azelaic acid itself in water in solubility determinations described below using shake flask methods and ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). In some embodiments, the solubility of azelaic acid can be increased by 19% by forming the supermolecular aggregates.
[0064] In some embodiments, the supermolecular aggregates formed by azelaic acid and at least one heterocyclic amino acid of Formula (I) in the present disclosure are co-crystals.
[0065] It has been found that the use of certain conditions (e.g., different preparation methods and / or different azelaic acid / proline stoichiometric ratios) can result in different supermolecular aggregates, including supermolecular aggregate I, supermolecular aggregate II, and supermolecular aggregate III described herein, which can exhibit one or more of the advantageous properties described herein.
[0066] Supramolecular aggregate I
[0067] In some embodiments, the supermolecular aggregates formed by azelaic acid and at least one heterocyclic amino acid of Formula (I) in the present disclosure are co-crystals.
[0068] In some embodiments, supermolecular aggregate I has a powder X-ray diffraction (sometimes referred to herein as PXRD) pattern substantially as shown in Figure 2 C. The 2Θ angles observed for supermolecular aggregate I in PXRD are shown in Table 1 below.
[0069] Table 1
[0070] Angle / 2 theta 5.7 8.5 9.4 16.7 17.6 18.5 19.4 20.3 21.1 21.8 23.0 23.6 27.3 28.3
[0071] In some embodiments, supermolecular aggregate I has a PXRD pattern comprising at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 peaks at the 2Θ angles, the relative intensities in the PXRD pattern being substantially as shown in Figure 2 C. The 2Θ angles observed for supermolecular aggregate I in PXRD are shown in Table 1 below.
[0072] It will be appreciated that the relative intensities can vary depending on a number of factors, including sample preparation, mounting, and the instrument and analysis procedures and settings used to obtain the spectra. The relative peak intensities and peak assignments can vary within experimental error.
[0073] In some embodiments, the peak assignments listed herein, including the peak assignment of supramolecular aggregate I, can vary by ±0.2 degrees or ±0.1 degrees 2θ. In some embodiments, the peak assignments listed herein, including the peak assignment of supramolecular aggregate I, can vary by ±0.2 degrees 2θ. In some embodiments, the peak assignments listed herein, including the peak assignment of supramolecular aggregate I, can vary by ±0.1 degrees 2θ.
[0074] In some embodiments, supramolecular aggregate I has essentially the following characteristics: Figure 1 The DSC (Differential Scanning Calorimetry) curve is shown in Figure D. In some embodiments, supramolecular aggregate I is characterized by endothermic reaction at approximately 78°C, as determined by DSC. In some embodiments, supramolecular aggregate I is characterized by endothermic reaction at approximately 78 ± 2°C (e.g., 78 ± 1.9°C, 78 ± 1.8°C, 78 ± 1.7°C, 78 ± 1.6°C, 78 ± 1.5°C, 78 ± 1.4°C, 78 ± 1.3°C, 78 ± 1.2°C, 78 ± 1.1°C, 78 ± 1°C, 78 ± 0.9°C, 78 ± 0.8°C, 78 ± 0.7°C, 78 ± 0.6°C, 78 ± 0.5°C, 78 ± 0.4°C, 78 ± 0.3°C, 78 ± 0.2°C, or 78 ± 0.1°C), as determined by DSC.
[0075] In some embodiments of supramolecular aggregate I, at least one or all of the following (a) to (d) apply:
[0076] (a) The supramolecular aggregate I has a PXRD pattern containing peaks at the following 2θ values: 5.7°±0.2°, 16.7°±0.2°, 17.6°±0.2°, 21.8°±0.2°, 23.0°±0.2°; or has a PXRD pattern containing peaks at the following 2θ values: 5.7°±0.2°, 8.5°±0.2°, 9.4°±0.2°, 16.7°±0.2°, 17.6°±0.2°, 18.5°±0.2°, 19.4°±0.2°, 20.3°±0.2°, 21.1°±0.2°, 21.8°±0.2°, 23.0°±0.2°, 23.6°±0.2°, 27.3°±0.2°, and 28.3°±0.2°.
[0077] (b) Supramolecular aggregate I has essentially the same properties as Figure 2 The PXRD pattern shown in C.
[0078] (c) The supramolecular aggregate I is characterized by endothermic reaction at about 78 °C, as determined by DSC.
[0079] (b) Supramolecular aggregate I has essentially the same properties as Figure 1 The DSC curve shown in Figure D.
[0080] Supramolecular aggregate II
[0081] In some embodiments, the supramolecular aggregate formed by azelaic acid and at least one heterocyclic amino acid of Formula (I) in the present disclosure is Supramolecular Aggregate II.
[0082] In some embodiments, Supramolecular Aggregate II has a PXRD pattern substantially as shown in Figure 2 B. The 2 theta angles observed for Supramolecular Aggregate II in PXRD are shown in Table 2 below.
[0083] Table 2
[0084] Angle / 2 theta 5.5 16.6 17.5 19.3 21.7 22.9
[0085] In some embodiments, Supramolecular Aggregate II has a PXRD pattern comprising at least 2, at least 3, at least 4, at least 5, or all of the peaks at the 2 theta angles, the relative intensities in the PXRD pattern being substantially as shown in Figure 2 B.
[0086] It is understood that the relative intensities can vary depending on a number of factors, including sample preparation, mounting, and the instrument and analysis procedures and settings used to obtain the spectra. The relative peak intensities and peak assignments can vary within experimental error.
[0087] In some embodiments, the peak assignments listed herein, including the peak assignments for Supramolecular Aggregate II, can vary by ±0.2 degrees or ±0.1 degrees 2 theta. In some embodiments, the peak assignments listed herein, including the peak assignments for Supramolecular Aggregate II, can vary by ±0.2 degrees 2 theta. In some embodiments, the peak assignments listed herein, including the peak assignments for Supramolecular Aggregate II, can vary by ±0.1 degrees 2 theta.
[0088] In some embodiments, Supramolecular Aggregate II has a PXRD pattern substantially as shown in Figure 1Supermolecular Aggregate II is characterized by two endotherms occurring at about 85 °C and 103 °C, as determined by DSC. In some embodiments, Supermolecular Aggregate II is characterized by two endotherms occurring at about 85 ± 2 °C (e.g., 85 ± 1.9 °C, 85 ± 1.8 °C, 85 ± 1.7 °C, 85 ± 1.6 °C, 85 ± 1.5 °C, 85 ± 1.4 °C, 85 ± 1.3 °C, 85 ± 1.2 °C, 85 ± 1.1 °C, 85 ± 1 °C, 85 ± 0.9 °C, 85 ± 0.8 °C, 85 ± 0.7 °C, 85 ± 0.6 °C, 85 ± 0.5 °C, 85 ± 0.4 °C, 85 ± 0.3 °C, 85 ± 0.2 °C, or 85 ± 0.1 °C) and 103 ± 2 °C (e.g., 103 ± 1.9 °C, 103 ± 1.8 °C, 103 ± 1.7 °C, 103 ± 1.6 °C, 103 ± 1.5 °C, 103 ± 1.4 °C, 103 ± 1.3 °C, 103 ± 1.2 °C, 103 ± 1.1 °C, 103 ± 1 °C, 103 ± 0.9 °C, 103 ± 0.8 °C, 103 ± 0.7 °C, 103 ± 0.6 °C, 103 ± 0.5 °C, 103 ± 0.4 °C, 103 ± 0.3 °C, 103 ± 0.2 °C, or 103 ± 0.1 °C), as determined by DSC.
[0089] In some embodiments of Supermolecular Aggregate II, at least one or all of the following (a) to (d) apply:
[0090] (a) Supermolecular Aggregate II has a PXRD pattern comprising peaks at 5.5° ± 0.2°, 16.6° ± 0.2°, 17.5° ± 0.2°, 21.7° ± 0.2°, 22.9° ± 0.2°; or a PXRD pattern comprising peaks at 5.5° ± 0.2°, 16.6° ± 0.2°, 17.5° ± 0.2°, 19.3° ± 0.2°, 21.7° ± 0.2°, and 22.9° ± 0.2°.
[0091] (b) Supermolecular Aggregate II has a PXRD pattern substantially as shown in Figure 2 B.
[0092] (c) Supermolecular Aggregate II is characterized by two endotherms occurring at about 85 °C and 103 °C, as determined by DSC.
[0093] (d) Supermolecular Aggregate II has a DSC curve substantially as shown in Figure 1 F.
[0094] Supramolecular aggregate III
[0095] In some embodiments, the supramolecular aggregate formed by azelaic acid and at least one heterocyclic amino acid of Formula (I) in the present disclosure is supramolecular aggregate III.
[0096] In some embodiments, supramolecular aggregate III has a PXRD pattern substantially as shown in Figure 2 D. The 2 theta angles observed for supramolecular aggregate III in PXRD are shown in Table 2 below.
[0097] Table 3
[0098] Angle / 2 theta 5.5 8.3 9.3 16.5 17.4 18.0 18.4 19.0 21.7 22.8 23.4 27.1 28.1
[0099] In one embodiment, supramolecular aggregate III has a PXRD pattern comprising at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 peaks at the 2 theta angles, the relative intensities in the PXRD pattern being as shown in Figure 2 D.
[0100] It is understood that the relative intensities can vary depending on a number of factors, including sample preparation, mounting, and the instrument and analysis procedures and settings used to obtain the spectra. The relative peak intensities and peak assignments can vary within experimental error.
[0101] In some embodiments, the peak assignments listed herein, including the peak assignments for supramolecular aggregate III, can vary by ± 0.2 degrees or ± 0.1 degrees 2 theta. In some embodiments, the peak assignments listed herein, including the peak assignments for supramolecular aggregate III, can vary by ± 0.2 degrees 2 theta. In some embodiments, the peak assignments listed herein, including the peak assignments for supramolecular aggregate III, can vary by ± 0.1 degrees 2 theta.
[0102] In some embodiments, supramolecular aggregate III has a PXRD pattern substantially as shown in Figure 1In some embodiments, Supramolecular Aggregate III is characterized by two endotherms occurring at about 77 °C and 95 °C, as determined by DSC. In some embodiments, Supramolecular Aggregate III is characterized by two endotherms occurring at about 77 ± 2 °C (e.g., 77 ± 1.9 °C, 77 ± 1.8 °C, 77 ± 1.7 °C, 77 ± 1.6 °C, 77 ± 1.5 °C, 77 ± 1.4 °C, 77 ± 1.3 °C, 77 ± 1.2 °C, 77 ± 1.1 °C, 77 ± 1 °C, 77 ± 0.9 °C, 77 ± 0.8 °C, 77 ± 0.7 °C, 77 ± 0.6 °C, 77 ± 0.5 °C, 77 ± 0.4 °C, 77 ± 0.3 °C, 77 ± 0.2 °C, or 77 ± 0.1 °C) and 95 ± 2 °C (e.g., 95 ± 1.9 °C, 95 ± 1.8 °C, 95 ± 1.7 °C, 95 ± 1.6 °C, 95 ± 1.5 °C, 95 ± 1.4 °C, 95 ± 1.3 °C, 95 ± 1.2 °C, 95 ± 1.1 °C, 95 ± 1 °C, 95 ± 0.9 °C, 95 ± 0.8 °C, 95 ± 0.7 °C, 95 ± 0.6 °C, 95 ± 0.5 °C, 95 ± 0.4 °C, 95 ± 0.3 °C, 95 ± 0.2 °C, or 95 ± 0.1 °C), as determined by DSC.
[0103] In some embodiments of Supramolecular Aggregate III, at least one or all of the following (a) to (d) apply:
[0104] (a) Supramolecular Aggregate II has a PXRD pattern comprising peaks at 5.5° ± 0.2°, 16.5° ± 0.2°, 17.4° ± 0.2°, 21.7° ± 0.2°, 22.8° ± 0.2°; or a PXRD pattern comprising peaks at 5.5° ± 0.2°, 8.3° ± 0.2°, 9.3° ± 0.2°, 16.5° ± 0.2°, 17.4° ± 0.2°, 18.0° ± 0.2°, 18.4° ± 0.2°, 19.0° ± 0.2°, 21.7° ± 0.2°, 22.8° ± 0.2°, 23.4° ± 0.2°, 27.1° ± 0.2°, and 28.1° ± 0.2°.
[0105] (b) Supramolecular Aggregate III has a PXRD pattern substantially as shown in FIG. 3D. Figure 2 D.
[0106] (c) Supramolecular Aggregate III is characterized by two endotherms occurring at about 77 °C and 95 °C, as determined by DSC.
[0107] (d) Supramolecular Aggregate III has a DSC profile substantially as shown in FIG. 3C. Figure 1 C.
[0108] III. Methods of manufacture
[0109] According to a second aspect, the present disclosure provides a method of preparing a supramolecular aggregate, comprising the steps of:
[0110] 1) mixing azelaic acid with at least one heterocyclic amino acid represented by general formula (I) below at a molar ratio of 1:2 to 2:1 to obtain a mixture;
[0111]
[0112] wherein R1and R2each independently represent hydrogen or hydroxyl, and at least one of R1and R2represents hydrogen; and
[0113] 2) subjecting the mixture to liquid-assisted grinding or cooling crystallization to obtain a supramolecular aggregate.
[0114] It should be noted that the following will adopt the same definitions as above for the features identical to those described above in "II. Supramolecular aggregate", such as "azelaic acid", "heterocyclic amino acid represented by formula (1)", and the like.
[0115] The raw material ratio has an important influence on the formation of azelaic acid supramolecular aggregates, including improving stability, crystallization uniformity, and solubility of azelaic acid. In order to obtain a supramolecular aggregate with the desired stability, crystallization uniformity, and improved solubility of azelaic acid, it is necessary to control the raw material ratio.
[0116] The present disclosure can form a supramolecular aggregate by setting the molar ratio of azelaic acid to the heterocyclic amino acid represented by general formula (I) in the range of 1:5 to 5:1, preferably 1:2 to 2:1, more preferably 1:1 to 2:1. Preferably, the molar ratio of azelaic acid to the heterocyclic amino acid represented by general formula (I) can be set to 1:1 to obtain excellent effects, including more homogeneous crystallization and more improved solubility of azelaic acid.
[0117] As a method of preparing a supramolecular aggregate, either of liquid-assisted grinding and cooling crystallization methods can be used. However, the liquid-assisted grinding method is preferably used because it can form more homogeneous crystallization. Liquid-assisted grinding includes adding a small amount of solvent and grinding the raw materials. As for the solvent used, there is no particular limitation as long as it can promote the interaction between the raw materials, enabling them to more easily form a supramolecular aggregate. In some embodiments, liquid-assisted grinding includes adding a good solvent for azelaic acid and the heterocyclic amino acid represented by general formula (I). As such a good solvent, a lower alkyl alcohol, such as a C1-C5 alkyl monohydric alcohol, preferably a C2-C3 alkyl monohydric alcohol, more preferably methanol, ethanol, or propanol, most preferably ethanol, can be used.
[0118] The amount of solvent (milling liquid) added in the liquid-assisted milling can be set to about 0.1 to 0.5 mL / g, in terms of the ratio of the volume of the lower saturated alkyl alcohol to the mass of the mixture of azelaic acid and the heterocyclic amino acid represented by Formula (I). Without wishing to be bound by theory, it is believed that if too much solvent is added in the liquid-assisted milling, the concentration of the raw materials in the solution can become too low, thereby reducing the opportunity for interaction between the raw materials and making it difficult for the formation of the co-crystal. Conversely, if too little solvent is added, the raw materials can not be sufficiently dissolved or dispersed in the solvent, which can also limit the interaction between the raw materials and thereby hinder the formation of the co-crystal.
[0119] The milling method in the liquid-assisted milling is not particularly limited. The milling can be performed manually using a mortar or using a milling device such as a mill.
[0120] In some embodiments, the liquid-assisted milling is performed using a lower saturated alkyl alcohol as the milling liquid, wherein the ratio of the volume of the lower saturated alkyl alcohol to the mass of the mixture of azelaic acid and the heterocyclic amino acid represented by Formula (I) is 0.1 to 0.5 mL / g.
[0121] In some embodiments, the liquid-assisted milling is performed using ethanol as the milling liquid, wherein the ratio of the volume of the ethanol to the mass of the mixture of azelaic acid and the heterocyclic amino acid is 0.1 to 0.5 mL / g, preferably the heterocyclic amino acid is proline.
[0122] IV. Cosmetic composition
[0123] According to a third aspect, the present disclosure provides a cosmetic composition comprising the above-described supramolecular aggregate.
[0124] It should be noted that the following for the features identical to those described in the above "II. Supramolecular aggregate" or "III. Production method", such as "azelaic acid", "heterocyclic amino acid represented by Formula (1)", and the like, will adopt the same definitions as the above.
[0125] The cosmetic composition can be in solid, semi-solid, or liquid form, and can be in the form of a solution, emulsion, suspension, or anhydrous form. If in the form of a solution or suspension, the composition can comprise about 1 to 99.9%, preferably about 5 to 95%, more preferably about 10 to 90% water. If in the form of an emulsion, the composition can comprise about 1 to 99%, preferably about 5 to 90%, more preferably about 10 to 85% water and about 1 to 99%, preferably about 5 to 90%, more preferably about 5 to 75% oil. If in the anhydrous form, the composition can comprise about 10 to 99% oil and 10 to 99% solidifying agent.
[0126] In one embodiment, the supramolecular aggregates are present in the cosmetic composition in an amount of from 0.01% to 50%, more preferably from 0.05% to 20%, more preferably from 0.1% to 10% by weight of azelaic acid, relative to the total amount of the composition.
[0127] The cosmetic composition can also comprise at least one cosmetically acceptable active ingredient, such as a moisturizer, an antioxidant, a UV screening agent, an anti-inflammatory agent, a preservative, a vitamin, a skin conditioning agent, a stabilizer, in particular for preventing or reducing excess sebum, acne, wrinkles, fine lines, skin dryness, photoaging, and inflammation, as long as the objectives of the present disclosure are achieved. Other cosmetically acceptable ingredients that can be mentioned include oils, thickening agents, pH adjusting agents, or any other ingredient that is typically formulated into a cosmetic or pharmaceutical. The following subsections provide non-limiting examples of some of these ingredients.
[0128] A. Moisturizers
[0129] The compositions of the present disclosure can contain one or more moisturizers. If present, they can comprise from about 0.1% to 75%, preferably from about 0.2% to 70%, more preferably from about 0.5% to 40%, by weight of the total composition. Examples of suitable moisturizers include ethylene glycol, sugars, hyaluronic acid, sodium hyaluronate, and the like. Preferably, the moisturizer used in the compositions of the present disclosure is a Ci-6, preferably C2-4, alkyl glycol, most particularly butylene glycol.
[0130] B. Antioxidants
[0131] The compositions of the present disclosure can contain one or more antioxidants. If present, they can comprise from about 0.001% to 20%, preferably from about 0.005% to 15%, more preferably from about 0.010% to 10%, by weight of the total composition.
[0132] Non-limiting examples of antioxidants that can be used in the compositions of the present disclosure include acetylcysteine, ascorbic acid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanol pectinate, ascorbyl palmitate, ascorbyl stearate, BHA, BHT, t-butyl hydroquinone, cysteine, cysteine HCI, dilauryl hydroquinone, di-t-butyl hydroquinone, dicetyl thiodipropionate, disodium ascorbyl sulfate, dilauryl thiodipropionate, ditridecyl thiodipropionate, dodecyl gallate, erythorbic acid, ascorbyl esters, ethyl ferulate, ferulic acid, gallate esters, hydroquinone, isooctyl thioglycolate, kojic acid, magnesium ascorbate, magnesium ascorbyl phosphate, methylsilanol ascorbate, natural botanical antioxidants (such as green tea or grape seed extract), nordihydroguaiaretic acid, octyl gallate, phenylthioglycolic acid, potassium sulfite, propyl gallate, quinones, rosmarinic acid, sodium ascorbate, sodium bisulfite, sodium erythorbate, sodium metabisulfite, sodium sulfite, superoxide dismutase, sodium thioglycolate, sorbityl furfural, thiodiglycol, thiodiglycolamide, thiodiglycolic acid, thioglycolic acid, thiolactic acid, thiosalicylic acid, and tris(nonylphenyl)phosphite.
[0133] C. UV Screens
[0134] The compositions of the present disclosure can contain one or more UV screening agents. If present, the UV screening agents can comprise from about 0.1% to 50%, preferably from about 0.5% to 40%, more preferably from about 1% to 35%, by weight of the total composition.
[0135] Non-limiting examples of UV screening agents include chemical UVA screening agents such as benzoylmethane compounds, dibenzal malonate derivatives, and the like, or UVB screening agents such as phenyl benzimidazole sulfonic acid, 2- ethylhexyl 2-cyano-3,3-diphenyl acrylate, methoxy cinnamic acid ethylhexyl ester, benzophenone derivatives, menthyl salicylate derivatives, and the like, or physical screening agents in particulate form. The addition of screening agents to the compositions provides additional protection to the skin during daylight hours and enhances the effectiveness of the skin lightening active ingredients on the skin.
[0136] The compositions of the present disclosure can be formulated to have a certain SPF (Sun Protection Factor) value, ranging from about 1 to 50, even 50+, depending on the type and dosage of UV screening agent. The calculation of the SPF value is well known in the art.
[0137] D. Anti-Inflammatory Agents
[0138] The compositions of the present disclosure can contain one or more anti-inflammatory agents. If present, the anti-inflammatory agent can comprise from about 0.001% to 5%, preferably from about 0.01% to 2%, more preferably from about 0.1% to 1%, by weight of the total composition.
[0139] Non-limiting examples of anti-inflammatory agents include steroidal anti-inflammatory agents and non-steroidal anti-inflammatory agents. The steroidal anti-inflammatory agent can be hydrocortisone. So-called "natural" anti-inflammatory agents are also useful. For example, bisabolol, aloe vera, Manjistha (extracted from plants of the genus Rubia, particularly Rubia cordifolia), and Guggal (extracted from plants of the genus Commiphora, particularly Commiphora mukul), Passiflora incarnata extract, Chamomile, and Sea Whip extract can also be used.
[0140] The inclusion of an anti-inflammatory agent in the composition will enhance the skin appearance benefits by, for example, contributing to uniformity and acceptable skin tone and / or color.
[0141] E. Preservatives
[0142] The compositions of the present disclosure can contain one or more preservatives. If present, the anti-inflammatory agent can comprise from about 0.001% to 8%, preferably from about 0.01% to 6%, more preferably from about 0.05% to 5%, by weight of the total composition.
[0143] Non-limiting examples of preservatives that can be used in the compositions of the present disclosure include quaternary ammonium preservatives, such as polyquatemium-1 and benzalkonium halides (e.g., benzalkonium chloride ("BAC") and benzalkonium bromide), parabens (e.g., methyl and propyl parabens), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal, or combinations thereof.
[0144] F. Vitamins
[0145] The compositions of the present disclosure can contain one or more vitamins. If present, the vitamin can comprise from about 0.001% to 20%, preferably from about 0.005% to 15%, more preferably from about 0.1% to 10%, by weight of the total composition.
[0146] Non-limiting examples of vitamins that can be used in the compositions of the present disclosure include tocopherol or derivatives thereof, such as tocopherol acetate, tocopherol ferulate, tocopherol polyphynyl ether-5, tocopherol polyphynyl ether-10, tocopherol polyphynyl ether-12, tocopherol polyphynyl ether-18, tocopherol polyphynyl ether-50, tocopherol, tocopherol enol ester, tocopherol linoleate, tocopherol nicotinate, tocopherol succinate dioleyl tocopherol methyl silanol; ascorbic acid or derivatives thereof, such as ascorbyl palmitate, magnesium ascorbyl phosphate; vitamin A or derivatives thereof, such as retinol palmitate; or vitamins D, K, B, or derivatives thereof.
[0147] G. Conditioning Agents
[0148] The compositions of the present disclosure can contain one or more skin / hair conditioning agents. If present, the skin conditioning agent can comprise from about 0.001% to 10%, preferably from about 0.01% to 5%, more preferably from about 0.1% to 2%, by weight of the total composition.
[0149] Non-limiting examples of skin / hair conditioning agents that can be used in the compositions of the present disclosure include RNA-Na (ribonucleic acid sodium); Vitamin B5 derivatives such as panthenol, dexpanthenol, pantothenyl ethyl ether, lauroyl lysine, hydrolyzed keratin, and hydrolyzed wheat protein.
[0150] H. Stabilizing Agents
[0151] The compositions of the present disclosure can contain one or more stabilizing agents. If present, the stabilizing agent can comprise from about 0.001% to 10%, preferably from about 0.01% to 5%, more preferably from about 0.1% to 2%, by weight of the total composition.
[0152] Non-limiting examples of stabilizing agents that can be used in the compositions of the present disclosure include sodium gluconate, sodium phytate, disodium EDTA, trisodium EDTA, tetrasodium EDTA.
[0153] I. Surfactants
[0154] The compositions of the present disclosure can contain one or more surfactants, especially when in the form of an emulsion. However, such surfactants can be used if the composition is also a solution, a suspension, or anhydrous. If present, the surfactant can comprise from about 0.01% to 30%, preferably from about 0.05% to 25%, more preferably from about 0.1% to 20%, by weight of the total composition.
[0155] Non-limiting examples of surfactants that can be used in the compositions of the present disclosure include nonionic organic surfactants such as Oleth-3, Oleth-5, Oleth-3 phosphate, Choleth-24, Ceteth-24, methyl gluceth-20; glycereth-26, PEG-75; silicone or silane based surfactants such as PEG-1 dimethicone, PEG-4 dimethicone, PEG-8 dimethicone, PEG-12 dimethicone, PEG-20 dimethicone, bis-PEG-18 methyl ether dimethyl silane, dimethicone copolyol; cetyl dimethicone copolyol, and the like.
[0156] J. Thickening Agents
[0157] Suitable thickeners can be incorporated into the compositions of the present disclosure. If present, the suggested range can be from about 0.01% to 30%, preferably from about 0.1% to 20%, more preferably from about 0.5% to 15%, by total weight of the composition.
[0158] Non-limiting examples of thickeners that can be used in the compositions of the present disclosure include animal, vegetable, mineral, silicone or synthetic waxes; silicas, silicates, silica silylates and their alkali or alkaline earth derivatives; silicone elastomers such as vinyl dimethicone / methicone silsesquioxane crosspolymer; polysaccharides such as agar, agarose, hyaluronic acid, hydroxyethylcellulose, methylcellulose, ethylcellulose, pectin, sclerotium gum, xanthan gum, dehydroxanthan gum, pectin, trehalose, gelatin and the like.
[0159] K. Oils
[0160] In cases where the compositions of the present disclosure are in the form of solutions, suspensions, anhydrous, particularly emulsions, the compositions can contain an oily ingredient. Oily ingredients are desirable for skin moisturizing and protective properties. Suitable oils include volatile silicones such as Dow Corning 244, 245, 344 and 200 fluids; volatile paraffins such as pentane, hexane, heptane, decane, dodecane, tetradecane, tridecane and C8-20isoparaffins as disclosed in U.S. Patent Nos. 3,439,088 and 3,818,105, both of which are hereby incorporated by reference; mono-, di- and tri-esters such as hexyl laurate, butyl isostearate, diisostearyl malate, neopentyl glycol dioctanoate, tributyl citrate, triisostearyl citrate; hydrocarbon oils such as mineral oil, phytol, squalene, squalane and the like.
[0161] The amount of these ingredients can be selected by one skilled in the art depending on the end use of the cosmetic composition. It will be understood by one skilled in the art that the compositions according to the present disclosure can comprise from about 20% to 98%, preferably from about 30% to 90%, more preferably from about 40% to 80% in total of one or more additional cosmetically acceptable ingredients.
[0162] The cosmetic composition can be in any form. Suitable forms include, but are not limited to, solid dose, liquid, gel, lotion, cream, hard gel stick, roll-on formulation, mousse, aerosol spray, pad application, and film forming formulation.
[0163] The cosmetic compositions of the present disclosure can also find wide application in the fields of personal care, food, dietary supplements, and pharmaceuticals, among others.
[0164] The present disclosure is not limited to these embodiments but can be modified by those skilled in the art within the scope of the claims attached hereto. The present disclosure also encompasses any embodiment obtained by the combination of the technical means disclosed in different embodiments within its technical scope. Examples
[0165] The following examples are given as non-limiting illustrations of the present disclosure.
[0166] 1. Sample preparation and characterization
[0167] The prepared supramolecular aggregates were characterized by DSC, PXRD and elemental analysis using the following procedures.
[0168] DSC
[0169] DSC analysis was performed using a HCT-1 thermal analyzer. The test was performed on a sample having a weight of 3 to 5 mg by heating at a heating rate of 5°C / min in the temperature range of 40°C to 200°C under a nitrogen atmosphere. -1
[0170] PXRD
[0171] Powder X-ray diffraction (PXRD) analysis was performed using a rotating anode X-ray powder diffractometer equipped with a Cu Kα source and operated at 40 kV and 40 mA. PXRD patterns were collected in the range of 2θ from 5 to 50° at an angular step of 1° / min.
[0172] Elemental Analysis
[0173] Elemental analysis was performed using a vario EL cube elemental analyzer to determine the composition of the prepared supramolecular aggregates. Specifically, the sample was completely combusted. The mass of the three products (CO2, H2O, N2) after oxidative combustion was determined by the elemental analyzer, and the content of the three elements (C, H, N) in the sample was determined, respectively.
[0174] The main raw materials used, trade names and suppliers are listed in Table 1.
[0175] Table 4. Raw material information
[0176] INCI Name Abbreviation Trade Name Supplier Azelaic Acid AZA Azelaic Acid Leyan Proline Pro L-Proline Sigma-Aldrich Ethanol EtOH Anhydrous Ethanol Shanghai Lingfeng Chemical Lysine Lys L-Lysine Macklin
[0177] Example 1. Preparation of supramolecular aggregate A
[0178] Supramolecular aggregate A (AZA-Pro(1:1)) was prepared using a liquid-assisted milling method. More specifically, after adding 0.2 mL of ethanol, 376 mg (2 mmol) of azelaic acid and 230 mg (2 mmol) of L-proline were milled in a mortar for 30 min to obtain supramolecular aggregate A as a microcrystalline powder. The obtained product was dried in an oven at 50 °C for 5 hours to remove residual solvent and then ground into a fine powder for further analysis.
[0179] Example 2. Preparation of supramolecular aggregate A
[0180] Supramolecular aggregate A (AZA-Pro(1:1)) was prepared using a cooling crystallization method. More specifically, 188 mg (1 mmol) of AZA and 115 mg (1 mmol) of L-Pro were dissolved in 4 mL of EtOH at a molar ratio of 1:1 to obtain a saturated solution. The saturated solution was heated to 45 °C and maintained at this temperature for 30 min with stirring to ensure complete dissolution of the starting materials. After complete dissolution, stirring was stopped, and the system was slightly cooled to room temperature. After further cooling to -7 °C, the system was allowed to stand for 6 hours. The resulting crystals were collected and dried under vacuum at 50 °C for 24 hours to obtain the pure form.
[0181] Examples 3-4. Preparation of supramolecular aggregates B and C
[0182] Except for adjusting the amounts of AZA and Pro as described in Table 5 below, supramolecular aggregates B (AZA-Pro(2:1)) and C (AZA-Pro(1:2)) were prepared using the same method as in Example 1.
[0183] Table 5. Raw material quantities and crystallization methods in Examples 1-4.
[0184]
[0185] Comparative Example 1. Preparation of supramolecular aggregate D
[0186] Supramolecular aggregate D (AZA-Lys(1:1)) was prepared using a liquid-assisted grinding method. More specifically, after adding 0.2 mL of ethanol, 376 mg (2 mmol) of azelaic acid and 292 mg (2 mmol) of L-lysine were ground in a mortar for 30 min to obtain supramolecular aggregate D as a microcrystalline powder. The obtained product was dried in an oven at 50 °C for 5 hours to remove residual solvent and then ground into a fine powder for further analysis.
[0187] Figure 1 and 2 The DSC and PXRD results of the raw materials AZA and Pro, as well as the supramolecular aggregates prepared in Examples 1-4, are shown respectively. Figure 3PXRD results of the starting materials AZA and Lys, and the supramolecular aggregates prepared in Comparative Example 1 are shown.
[0188] Table 6 below shows the DSC endothermic peaks of the starting materials AZA and Pro, and the supramolecular aggregates prepared in Examples 1-4.
[0189] Table 6.
[0190] Endothermic Peak AZA 103℃ Pro 219℃ Example 1 78℃ Example 2 75℃,103℃ Example 3 77℃,95℃ Example 4 86℃,103℃
[0191] As Figure 1 shown, the melting temperatures of AZA and L-Pro are 103 °C and 219 °C, respectively. The supramolecular aggregate A prepared in Example 1 using liquid-assisted grinding at a molar ratio of 1 : 1 only shows a very weak endothermic peak at 78 °C, which is significantly different from AZA and Pro. This phenomenon indicates that a homogeneous supramolecular aggregate (supramolecular aggregate I) is formed in Example 1. In contrast, the supramolecular aggregate A prepared in Example 2 using cooling crystallization at a molar ratio of 1 : 1 shows a weak endothermic peak at 75 °C and also shows an endothermic peak at 103 °C corresponding to AZA. This suggests that liquid-assisted grinding is more suitable for the formation of a eutectic between AZA and Pro than cooling crystallization.
[0192] In addition, the supramolecular aggregate B prepared in Example 3 using liquid-assisted grinding at a molar ratio of 2: 1 shows two endothermic peaks, where the first endothermic peak is significant, representing the melting point of the eutectic (77 °C), and the second endothermic peak is weak, corresponding to the interaction between AZA and Pro (95 °C). This indicates that the eutectic formation (supramolecular aggregate II) in Example 3 is more complete. Further, the supramolecular aggregate C prepared in Example 4 using liquid-assisted grinding at a molar ratio of 1 : 2 also shows two endothermic peaks. The first endothermic peak (86 °C) is weak, and the second endothermic peak corresponds to the melting point of AZA (103 °C). This indicates that the eutectic formation in Example 4 (supramolecular aggregate III) is not complete.
[0193] Table 7 below shows the PXRD data of the starting materials AZA and Pro, and the eutectics from Example 1, Example 3, and Example 4.
[0194] Table 7.
[0195]
[0196] From Figure 2As can be seen from Table 7, the supramolecular aggregate I obtained in Example 1 showed distinct characteristic peaks at least at 2θ of 5.7°, 20.3° and 21.8°, which were different from those of AZA and Pro, indicating the formation of a co-crystal. The supramolecular aggregate II and the supramolecular aggregate III in Examples 3 and 4 showed distinct characteristic peaks at least at 2θ of 5.5° and 21.7°, which were different from those of AZA and Pro, indicating the formation of a co-crystal.
[0197] On the other hand, as shown in Table 8, the solubility of AZA in distilled water was increased by about 1.19 times, from 2352 ppm of the raw material AZA to 2795 ppm of the supramolecular aggregate. Figure 3 As shown in Table 8, the solubility of AZA in distilled water was increased by about 1.19 times, from 2352 ppm of the raw material AZA to 2795 ppm of the supramolecular aggregate.
[0198] In addition, the results of elemental analysis showed that the measured contents of carbon, hydrogen, and nitrogen elements in the supramolecular aggregates prepared in Examples 1 to 4 and Comparative Example 1 were close to the theoretical values, indicating that the supramolecular aggregates of different molar ratios were successfully prepared.
[0199] 2. Solubility test
[0200] The solubility test was performed using a shake flask method and ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). Specifically, an excess sample equivalent to 30 mg of AZA was dispersed in a test tube containing 1.5 mL of distilled water, respectively. The dispersion was placed in a water bath and continuously ultrasonicated for 30 minutes. Then, the dispersion was centrifuged at a speed of 6000 rpm for 50 minutes. In addition, the AZA concentration in the supernatant of the raw material AZA and the supramolecular aggregate of Example 1 was evaluated by UPLC-MS.
[0201] The UPLC-MS analysis was performed using a Waters UPLC / MS (Waters ACQUITY I class-TQS micro MS detector) and a C18 reverse phase column (Phenomenex Prodigy ODS-3 column; 5 μm, 150 x 4.6 mm inner diameter). The mobile phase consisted of acetonitrile and formic acid aqueous solution. The gradient flow rate of the mobile phase was set to 0.6 mL / min. The column temperature, sample injection volume, and detection m / z were set to 40°C, 5 μl, and 187>125 (negative), respectively. The calibration curve of AZA was linear in the concentration range of 0.2 to 20 μg / mL (r 2 ≥ 0.995).
[0202] As shown in Table 8, the solubility of AZA in distilled water was increased by about 1.19 times, from 2352 ppm of the raw material AZA to 2795 ppm of the supramolecular aggregate.
[0203] Table 8. Solubility in water
[0204]
[0205] 3. Formulation
[0206] Example 5 and Comparative Examples 2-3 were prepared according to the formulations shown in Table 9.
[0207] Table 9. Formulations of Example 5 and Comparative Examples 2-3
[0208]
[0209] As a result, both Comparative Example 2 and Comparative Example 3 had a problem in that AZA was not completely dissolved, while this problem was not observed in Example 5.
[0210] It can be seen that the supramolecular aggregate of the present application can be used to prepare a water-based cosmetic having a higher content of AZA.
[0211] While the disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the disclosure as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed, that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein can be utilized. Accordingly, the appended claims are intended to include within their scope all such processes, machines, manufacture, compositions of matter, means, methods, or steps.
Claims
1. Supramolecular aggregates formed from azelaic acid and at least one heterocyclic amino acid of the general formula (I), ###0001### wherein R1 and R2 each independently represent hydrogen or hydroxyl, and at least one of R1 and R2 represents hydrogen; and the powder X-ray diffractogram of the aggregates comprises peaks at 2Θ of 5.7° ± 0.2° and 21.8° ± 0.2°. wherein the powder X-ray diffractogram further comprises at least 2, preferably at least 4 characteristic peaks at 2Θ of 8.5° ± 0.2°, 9.4° ± 0.2°, 16.7° ± 0.2°, 17.6° ± 0.2°, 18.5° ± 0.2°, 19.4° ± 0.2°, 20.3° ± 0.2°, 21.1° ± 0.2°, 23.0° ± 0.2°, 23.6° ± 0.2°, 27.3° ± 0.2° and 28.3° ± 0.2°.
2. The supramolecular aggregate of claim 1, wherein, the powder X-ray diffractogram further comprises at least 2, preferably at least 4 characteristic peaks at 2Θ of 16.6° ± 0.2°, 17.5° ± 0.2°, 19.3° ± 0.2° and 22.9° ± 0.2°.
3. The supramolecular aggregate of claim 1, wherein, the powder X-ray diffractogram further comprises at least 2, preferably at least 4 characteristic peaks at 2Θ of 8.3° ± 0.2°, 9.3° ± 0.2°, 16.5° ± 0.2°, 17.4° ± 0.2°, 18.0° ± 0.2°, 18.4° ± 0.2°, 19.0° ± 0.2°, 22.8° ± 0.2°, 23.4° ± 0.2°, 27.1° ± 0.2° and 28.1° ± 0.2°.
4. The supramolecular aggregate of claim 1, wherein, the heterocyclic amino acid is proline or hydroxyproline, preferably proline.
5. The supramolecular aggregate according to any one of claims 1 to 4, wherein, the molar ratio of azelaic acid to proline is 1 :5 to 5: 1, preferably 1 :2 to 2: 1, more preferably 1 : 1 to 2:
1.
6. The supramolecular aggregate according to any one of claims 1 to 5, wherein, the aggregates show one endothermic peak in their DSC curve at a temperature of 76°C to 86°C.
7. The supramolecular aggregate according to any one of claims 1 to 6, wherein, 8. The supramolecular aggregates according to claim 7, wherein the aggregates further show one endothermic peak in their DSC curve at a temperature of 94°C to 103°C.
9. A process for the preparation of supramolecular aggregates from azelaic acid and a heterocyclic amino acid, comprising the following steps: 1) mixing azelaic acid with at least one heterocyclic amino acid of the general formula (I) in a molar ratio of 1 :2 to 2: 1, preferably 1 : 1 to 2: 1, more preferably 1 : 1, to obtain a mixture; wherein R1 and R2 each independently represent hydrogen or hydroxyl, and at least one of R1 and R2 represents hydrogen; and 2) subjecting the mixture to liquid-assisted milling or cooling crystallization to obtain the supramolecular aggregates. the liquid-assisted milling is performed using a lower saturated alkyl alcohol as milling liquid, wherein the ratio of the volume of the lower saturated alkyl alcohol to the mass of the mixture is 0.1 to 0.5 ml / g.
10. The method of claim 9, wherein, the lower saturated alkyl alcohol is ethanol.
11. The method of claim 9 or 10, wherein, the heterocyclic amino acid is proline or hydroxyproline, preferably proline.
12. The method of any one of claims 9-11, wherein, 13. A cosmetic composition comprising the supramolecular aggregates according to any one of claims 1 to 8. 14. The cosmetic composition according to claim 13, wherein the composition further comprises at least one active ingredient selected from the group consisting of humectants, antioxidants, UV screening agents, anti-inflammatory agents, preservatives, vitamins, skin conditioning agents, stabilizing agents, and mixtures thereof.
